香菇多糖联合多西他赛对胃癌BGC823细胞增殖的影响  

The effect of lentinan and docetaxel on the proliferation of BGC823 cells

作　　者：赵力[1] 李午生[1] 李凯[1] 肖玉平[2] 

机构地区：[1]中国医科大学附属盛京医院肿瘤1科,辽宁沈阳110022 [2]中国医科大学附属第一医院肿瘤研究所胃肠肿瘤病理研究室,普通外科研究所肿瘤病理研究室,辽宁沈阳110001

出　　处：《现代肿瘤医学》2013年第10期2173-2176,共4页Journal of Modern Oncology

摘　　要：目的:观察香菇多糖单药及联合多西他赛抑制胃癌细胞BGC823增殖的作用。方法:分别用不同浓度的香菇多糖、多西他赛和香菇多糖联合多西他赛处理胃癌细胞BGC823。香菇多糖终浓度分别为1.560μg/ml,3.125μg/ml,6.250μg/ml,12.500μg/ml。多西他赛终浓度分别为0.625μg/ml,1.250μg/ml,2.500μg/ml,5.000μg/ml。MTT法检测各组细胞增殖情况;同时用Annexin V/PI法检测各组细胞的凋亡。结果:单药香菇多糖能抑制BCG823细胞的增殖,不同浓度(由高到低)对BGC823细胞的增殖抑制率分别为67.7%,56.0%、42.1%和23.2%,与阴性对照组比较有统计学意义(P<0.05)。不同浓度香菇多糖联合多西他赛能增强多西他赛对BGC823细胞增殖的抑制作用。单药香菇多糖能增加BGC823细胞的细胞凋亡率,与多西他赛联用使细胞凋亡率明显增加(P<0.05)。结论:香菇多糖能抑制胃癌BGC823细胞的增殖,并能显著增强多西他赛抑制胃癌细胞BGC823的增殖作用。Objective：To investigate whether lentinan, lentinan combined with docetaxel can inhibit the cell prolif- eration in human gastric cancer cell line BGC823. Methods：BGC823 cells were divide into lentinan, doeetaxel and lentinan combined docetaxel groups. Lentinan was added in the cuhuremedium to concentration of 1. 560μg/ml, 3. 125μg/m1,6. 250μg/ml, 12.5001xg/ml. Docetaxel was added in the culturemedium to concentration of 0. 625μg/ ml, 1. 250μg/rn1,2. 500μg/m1,5. 0001xg,/ml. MTT was applied to detect the proliferation of BGC823 cells. Apoptosis was detected by Annexin V/PI. Results： Lentinan could inhibit the proliferation of BGC823. Compared with the control group, the inhibitary rates were 67.7% ,56.0% ,42.1% and 23.2% with different concentrations of lentin- an（P 〈0.05） . The inhibitory rates of the proliferation of BGC823 ceils were significantly higher in combined with docetaxel than those in docetaxel alone group（P 〈 0.05 ）. Lentinan can increase the apoptosis rates of BGC823 cells, the apoptosis rate was higher in combined with docetaxel group （ P 〈 0.05 ）. Conclusion： Lentinan can inhibit the pro- liferation of gastric cancer BGC823 cells, and can significantly enhance the inhibit rate of proliferation in docetaxel.

关 键 词：香菇多糖 多西他赛 细胞增殖 细胞凋亡 胃癌BGC823细胞 

分 类 号：R73-361[医药卫生—肿瘤] R735.2[医药卫生—临床医学]